以肠道菌群为靶点治疗原发性胆汁性胆管炎的临床应用

Treatment of primary biliary cholangitis by targeting intestinal flora

原发性胆汁性胆管炎(PBC)是一种以胆管上皮细胞为特征性靶标的进行性胆汁淤积性肝病。“疾病肠治”是近年的研究热点。未来或可通过益生菌改善肠道菌群丰度及分布,重塑肠道微环境,进而干预PBC疾病进展。本文从肠道菌群角度及益生菌的临床应用方面进行综述,为PBC寻找新的治疗策略提供思路。

Primary biliary cholangitis(PBC)is a progressive cholestatic liver disease targeting biliary epithelial cells,and the concept of“treating diseases by intervening with the gut”has become a research hotspot in recent years.In the future,probiotics may be used to improve the abundance and distribution of intestinal flora,reshape the intestinal microenvironment,and intervene against the progression of PBC.This article reviews the gut microbiota and the clinical application of probiotics,so as to provide ideas for finding new treatment strategies for PBC.